Candidiasis Infections and Infestations
Conditions
Interventions
Workpackage 2: 100 yeast isolates from blood, found during routine diagnostics in 4 Dutch hospitals, will be collected. The isolates, together with some patient information (age, gender) will be used
Sponsors
National Institute for Public Health and the Environment
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: WP2 & WP4a: Patients with a positive yeast culture from blood or other sterile sites. Added 23/01/2026: Inclusion was performed retrospectively and was completed in November 2025. WP3: Patients in the ICU and patients outside of the ICU who were in contact with C. auris-positive patients. Added 23/01/2026: Inclusion was completed in January 2026. WP4b: Patients tested positive for C. auris. Added 23/01/2026: Inclusion is still ongoing.
Exclusion criteria
Exclusion criteria: Patients who object to participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| WP2: Determination and susceptibility testing is performed on the yeast isolates found in blood, using the hospitals' own protocols. The isolates will also be sent to the national reference center to verify the results using EUCAST. WP3: The best body locations for screening of C. auris will be tested by taking swabs from different body sites. To determine the best method for the detection of C. auris, different methods for culturing and molecular detection (PCR and LAMP) are compared using the swabs. WP4a: Determination and susceptibility testing will be done in the same manner as for WP2. The isolates collected for WP2 and WP4 will also be sequenced by the national reference center using Illumina sequencing. WP4B: Wastewater samples will be collected once a month in each center, serving as background data, and partially as a negative control. When proven C. auris colonized patients are admitted, wastewater sampling can be intensified. | — |
Secondary
| Measure | Time frame |
|---|---|
| WP4B: All C. auris isolates found during MDRO screening at the participating hospitals will be send to the national reference center for determination, susceptibility testing using EUCAST, and whole genome sequencing using Illumina sequencing. | — |
Countries
Greece, Netherlands
Contacts
Public ContactEelco Meijer
Outcome results
None listed